ALV-100
Low EvidenceA bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.
What It Is
ALV-100 is a bifunctional peptide that combines glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor (GLP-1R) agonism in a single molecule. It is the lead candidate of Alveus Therapeutics, a Philadelphia-based obesity and metabolic-disease company (with research operations in Copenhagen, Denmark) that emerged from stealth on January 8, 2026 with a $159.8 million Series A led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds; the round was later upsized to roughly $197 million in a second and final close in February 2026. The molecule pairs GLP-1 receptor agonism, which drives appetite suppression and weight loss, with GIPR antagonism, a genetically validated pathway that the company links to improved quality of weight loss (preserving lean mass relative to fat) and more durable long-term maintenance. Mechanistically it sits in the same GIPR-antagonist + GLP-1 design space as Amgen's MariTide (maridebart cafraglutide). On January 23, 2026, Alveus announced FDA clearance of its Investigational New Drug (IND) application and dosing of the first patient in a Phase 1b trial of ALV-100 for obesity. Alveus is also advancing a differentiated amylin pipeline, including ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist expected to enter first-in-human studies within roughly 18 months. ALV-100 is one of the most heavily financed new obesity peptides to enter the clinic in early 2026 and reflects the field's shift toward combination and lean-mass-sparing mechanisms.
Regulatory Status
FDA cleared the IND and the first patient was dosed in a Phase 1b obesity trial in January 2026. Not approved in any jurisdiction.
Effective: 2026
View FDA SourceWhy Researchers Study It
ALV-100 represents the GIPR-antagonist plus GLP-1-agonist combination class — the same broad mechanism as Amgen's MariTide — that aims to deliver durable weight loss with better preservation of lean mass and stronger weight maintenance after the active phase. Researchers study it because layering GIPR antagonism onto GLP-1 agonism may improve the quality and durability of weight loss beyond what single-mechanism GLP-1 drugs achieve, and because the asset is well financed and already in the clinic.
Proposed Mechanisms
- Agonizes the GLP-1 receptor to suppress appetite and reduce body weight
- Antagonizes (blocks) the GIP receptor, a pathway linked to the quality and durability of weight loss
- Bifunctional single-molecule design intended to preserve lean mass relative to fat loss
- Aims to improve long-term weight maintenance after the active weight-loss phase
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Company / financing | Alveus Therapeutics emergence from stealth with Series A financing | Launched Jan 8, 2026 with $159.8M Series A (upsized to ~$197M in Feb 2026) to advance ALV-100 and an amylin pipeline | Source |
| Human (Phase 1b, ongoing) | First-in-human Phase 1b obesity trial | FDA cleared the IND and first patient dosed in late January 2026; clinical efficacy data not yet reported | Source |
Commonly Discussed Benefits
Researching ALV-100? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Only early clinical-stage (Phase 1b) status; no human efficacy data reported yet
- Human weight-loss magnitude and lean-mass benefit not established
- Long-term safety and efficacy unknown
- Available only through clinical trial enrollment
- Not FDA-approved; not a compounding-eligible peptide
Comparisons
See how ALV-100 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Alveus Therapeutics Launches with $160 Million Series A Financing (Jan 8, 2026) PubMed
- [2] Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 (Jan 23, 2026) PubMed
- [3] BioPharma Dive — Alveus launches with $160M to advance MariTide-like obesity drug PubMed
Keep researching in the app
- Log ALV-100 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.
Maridebart Cafraglutide (MariTide)
Medium EvidenceAmgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.
AT7687
Low EvidenceA first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression.
ALV-200
Low EvidenceALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing.